Evidence map›Paper›PMID 36296242›Full record

ArticleMicroorganisms2022

Targeting the Bet-Hedging Strategy with an Inhibitor of Bacterial Efflux Capacity Enhances Antibiotic Efficiency and Ameliorates Bacterial Persistence In Vitro.

Demosthenes Morales, Sofiya Micheva-Viteva, Samantha Adikari, James Werner, Murray Wolinsky, Elizabeth Hong-Geller, Jinwoo Kim, Iwao Ojima

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Demosthenes MoralesBioscience Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Sofiya Micheva-VitevaBioscience Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.ORCID 0000-0002-2693-4333
Samantha AdikariBioscience Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
James WernerCenter for Integrated Nanotechnologies, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Murray WolinskyBioscience Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Elizabeth Hong-GellerBioscience Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Jinwoo KimInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY 11794, USA.
Iwao OjimaInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY 11794, USA.ORCID 0000-0002-3628-1161
Los Alamos National Laboratory · USStony Brook University · US

Funding

Defense Threat Reduction Agency HDTRA12-3-2-0002Los Alamos National Laboratory R&D (LDRD) 20200222DR
6 · The paper itself

Abstract

Persistence is a bet-hedging strategy in bacterial populations that increases antibiotic tolerance and leads to the establishment of latent infections. In this study, we demonstrated that a synthetic non-toxic taxane-based reversal agent (tRA), developed as an inhibitor of ABC transporter systems in mammalian cancer cells, enhanced antibiotic killing of persister populations from different pathogens, including

Indexed as

antibiotic therapy enhancementbacterial persistenceBurkholderiaefflux inhibitorhistone deacetylase inhibitionpolyketide synthase

Identifiers

PMID36296242
PMCPMC9609472
OpenAlexW4303856833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.